DeepSeek Speeds AI 85% 🧠 11K humanoid Robots Sold 🤖 China EVs in EU Factories 🚗

2026-07-06 | subscribe | homepage

Welcome back to China Insights Weekly. Here are some of the key highlights for this week’s edition:

• Solid-tumor CAR-T first, as China pushes advanced cell therapy into a new market

• Portable ACs surge in Europe, with Chinese brands riding heatwave demand

• Engineering majors dominate admissions, aligning students with industrial policy

• Clean-energy targets tighten, from provincial quotas to heavy-industry surcharges

Remember to follow us on LinkedIn, X or Facebook.

🚀 Headlines

DeepSeek breakthrough speeds up LLM generation by 85%, Meituan open-sources new top-performing LLM (link, link)

DeepSeek has open-sourced DSpark, a speculative decoding framework that speeds LLM inference by up to 85%. Under an MIT license, it lifts aggregate throughput by 51% for DeepSeek-V4-Flash and 52% for V4-Pro, with per-user gains of 60-85% and 57-78% versus MTP-1. DSpark works with other open models, including Qwen, via released checkpoints. It combines semi-autoregressive drafting with confidence-scheduled verification, reducing wasted computation and making self-hosted inference faster and cheaper for teams constrained by U.S. model access limits.

Meituan open-sourced LongCat-2.0, a 1.6-trillion-parameter Mixture-of-Experts model with a 1-million-token context window, under an MIT license. It scored 59.5 on SWE-bench Pro and placed in OpenRouter’s top three at 10.1 trillion monthly tokens. Trained on over 50,000 domestic ASICs, it is one of the strongest signals that frontier AI performance can scale without Nvidia dependence. Standard pricing is USD 0.75/USD 2.95 per million tokens; promotional rates run at USD 0.30/USD 1.20. The launch supports demand for lower-cost, open-source alternatives amid U.S. restrictions on GPT-5.6 and Claude Fable 5.

UBTECH brings consumer humanoids to market with 11,000 preorders (link)

UBTECH has unveiled its first consumer humanoid, the U1, under the UWorld brand. The lineup includes Lite, Pro and Ultra models, with pre-orders above 11,000 since opening on June 2. The 1.60m–1.85m robots combine 88 high-degree-of-freedom joints and an emotional AI layer for long-term interaction; core data stays stored locally and encrypted. Founder Zhou Jian said delivery starts in September. The move marks UBTECH’s push into consumer robotics and signals an important transition from industrial-only applications to households.

China's EV makers are taking over the European factories; CATL and Ford start production at US battery plant (link, link)

Chinese EV makers are moving into Europe's idle factories while avoiding EU import duties. Chery will build EVs at a former Nissan plant in Barcelona and is in talks over Nissan’s Sunderland site. Geely is reportedly taking over part of a former Ford plant near Valencia, while BYD is reportedly eyeing half of Volkswagen’s Dresden plant. Chinese brands sold 285,000 cars in Europe in Q1 2026, up 88% year-on-year, lifting share from 4.5% to above 8%. The shift is giving Chinese players local production access, distribution links, and brand legitimacy, while European makers face deeper supplier dependency on Chinese platforms and batteries.

CATL has commenced production at its Michigan battery plant through a technology-licensing agreement with Ford, marking a shift from exports to an integrated investment-trade model. Originally scaled at USD 3.5 billion for 35 GWh capacity, the project was reduced to USD 2 billion and 20 GWh following political scrutiny and policy uncertainty. The plant will supply LFP cells for Ford's electric pickups, with first deliveries expected in 2026. This comes as Ford recorded USD 19.5 billion in EV-related impairment losses after the US ended tax credits. CATL's global network of battery swap stations has reached 2,000 across 180 Chinese cities, targeting 3,000 by the end of 2026.

China approved the world’s first solid tumor CAR-T therapy (link)

China has approved the first solid-tumor CAR-T therapy. On June 22, the NMPA approved CARsgen Therapeutics to market satri-cel for advanced HER2-negative, Claudin18.2-positive gastric cancer. The treatment was developed by CARsgen and marks a major breakthrough in a field historically dominated by blood cancers. A U.S. clinical trial was put on hold in 2023 due to manufacturing issues at its North Carolina site, and US approval pace remains slower overall, while China pushes cell therapy commercialization faster.

Chinese portable split air conditioners see sales boom as Europe swelters (link)

A severe heatwave in Europe is driving a surge in Chinese portable split ACs. Midea reported over 70% year-on-year sales growth in France, Spain, Germany, and the UK; Gree saw more than 40% growth in France, Italy and Spain in H1. Drill-free portable units, with no permanent installation, are selling much faster than conventional systems whose install slots are full into August. Exports of these units are up 70% in the first five months, while overall household AC exports to Western Europe rose nearly 10%. Chinese producers are leaning on the China-Europe Railway Express to protect lead times.